Nordic Nanovector to terminate Phase IIb follicular lymphoma trial
The company will now shift the focus on the development of its pipeline of CD37-targeting products.
Vishnu Priyan
Latest articles
All Articles
CIHR awards grant for COVID-19 Network of Clinical Trials Networks
The network will progress to support critical research capacity among a national network of over 60 sites with the…
Alterity obtains authorisation in Italy for Phase II trial of multiple system atrophy therapy
The randomised, double-blind, placebo-controlled trial will analyse ATH434 in early-stage MSA patients.
Altamira reaches target enrolment in acute Covid-19 nasal spray trial
The trial of Bentrio nasal spray in acute Covid-19 patients is being carried out in Bulgaria and North Macedonia.
Velocity, Coastal Heart Medical partner to transform specialty care
This collaboration intends to boost clinical research opportunities available to all patients including minorities.
Moderna’s booster shot shows antibody response against Omicron subvariants
The company plans to make regulatory submissions seeking update to the composition of the booster vaccine to mRNA-1273.214.
Biomea doses first subject in multiple myeloma cohort of Phase I trial
The trial will analyse the safety, tolerability and pharmacokinetics / pharmacodynamics of a once-a-day dose of BMF-219.
Florence raises funds to double output of clinical trials
Utilising SiteLink, sponsors can now connect to sites remotely for all phases and treatment areas of the trials.
AstraZeneca-Ionis’ eplontersen meets endpoints in Phase III ATTRv-PN trial
Eplontersen was found to have a favourable safety and tolerability profile without any particular concerns in the trial.